TTPH
(NASDAQ)
2.24
-0.1836  (-8.20%)
Volume (24h): 427.74K Day Range: 2.11 - 2.40
Market Cap: 17.72M 52W Range: 0.2250 - 6.17
May-29-20 12:43PM Tetraphase Announces Second Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased ConsiderationBusiness Wire
12:30PM AcelRx Pharmaceuticals Announces Revised Merger Agreement with TetraphasePR Newswire
May-28-20 12:24PM The Daily Biotech Pulse: PhaseBio To Start Potential Pivotal COVID-19 Trial, Immunomedics CEO Quits, Tetraphase Receives Sweetened OfferBenzinga
12:55AM Tetraphase Announces Receipt of Amended Melinta Proposal, Determination of Superior Offer and Notice to AcelRxBusiness Wire
May-27-20 01:54PM AcelRx Pharmaceuticals Announces Revised Merger Agreement with TetraphasePR Newswire
01:25PM Tetraphase Announces Amendment to Merger Agreement with AcelRx Pharmaceuticals for Increased ConsiderationBusiness Wire
May-22-20 11:10AM The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID FrayBenzinga
01:55AM Tetraphase Announces Determination of Superior Offer and Notice to AcelRxBusiness Wire
May-12-20 02:17PM Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues MissZacks
May-07-20 11:50PM Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Lags Revenue EstimatesZacks
08:15PM Tetraphase Pharmaceuticals Reports First Quarter 2020 Financial Results and Highlights Recent Corporate DevelopmentsBusiness Wire
May-07-20 04:55PM Bidding War Sends Tetraphase Shares SoaringBenzinga
11:41AM The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500Benzinga
May-06-20 04:30PM Will Tetraphase Pharmaceuticals (TTPH) Report Negative Q1 Earnings? What You Should KnowZacks
May-05-20 08:39PM SHAREHOLDER ALERT: WeissLaw LLP Reminds ETFC, TCO, TERP, and TTPH Shareholders About Its Ongoing InvestigationsGlobeNewswire
04:51PM Tetraphase (TTPH) to Post Q1 Earnings: What's in the Cards?Zacks
Apr-30-20 09:18PM Lifshitz Law Firm, P.C. Announces Investigation of CenterState Bank Corporation (CSFL), resTORbio, Inc. (TORC), Tetraphase Pharmaceuticals, Inc. (TTPH), and The Meet Group, Inc. (MEET)GlobeNewswire
03:30AM Rigrodsky & Long, P.A. Files Class Action Suit Against Tetraphase Pharmaceuticals, Inc.ACCESSWIRE
Apr-28-20 10:56PM SHAREHOLDER ALERT: WeissLaw LLP Reminds TTPH, TERP, LM, and ETFC Shareholders About Its Ongoing InvestigationsGlobeNewswire
Apr-27-20 05:50PM TTPH, FSB, FG, and OPB SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MergersGlobeNewswire
Apr-21-20 11:55PM INVESTOR ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - WLTW, TTPH, TERPACCESSWIRE
10:00PM SHAREHOLDER ALERT: WeissLaw LLP Reminds LM, TERP, and TTPH Shareholders About Its Ongoing InvestigationsGlobeNewswire
Apr-21-20 05:00PM SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - FG, OPB, TTPHACCESSWIRE
02:34PM NTGN, ETFC, TTPH, and MINI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MergersGlobeNewswire
Apr-21-20 01:56AM SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Mergers; Are Shareholders Getting a Fair Deal?PR Newswire
Apr-14-20 10:18PM SHAREHOLDER ALERT: WeissLaw LLP Reminds XPER, TIVO, and TTPH Shareholders About Its Ongoing InvestigationsGlobeNewswire
06:15PM IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies - WLTW, TTPH, TERPACCESSWIRE
Apr-14-20 02:58PM ETFC, TTPH, TERP, and MINI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MergersGlobeNewswire
Apr-10-20 06:50PM SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies - WLTW, TTPH, TERPACCESSWIRE
01:00PM SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Tetraphase Pharmaceuticals, Inc. - TTPHPR Newswire
Apr-07-20 02:00PM Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - WLTW, TTPH, TERPACCESSWIRE
Apr-02-20 08:46PM TTPH, TERP, MEET, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MergersGlobeNewswire
Mar-24-20 03:36PM TTPH, TCO, LM, and WLTW SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MergersGlobeNewswire
Mar-19-20 05:55PM SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - WLTW, TTPH, TERPACCESSWIRE
Mar-18-20 09:41PM Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of SB ONE, Tetraphase Pharmaceuticals, AVX, and Front Yard on behalf of Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
05:52PM Moore Kuehn Encourages DLPH, CSFL, TTPH, and FSCT Investors to Contact Law FirmPR Newswire
Mar-18-20 05:36PM TETRAPHASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Tetraphase Pharmaceuticals, Inc. - TTPHBusiness Wire
Mar-17-20 10:35PM SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Tetraphase Pharmaceuticals, Inc. (NASDAQ-TTPH)ACCESSWIRE
09:50PM SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tetraphase Pharmaceuticals, Inc. with AcelRx Pharmaceuticals, Inc. is Fair to TTPH ShareholdersACCESSWIRE
Mar-17-20 06:30PM SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Sale of These Companies; Are Shareholders Getting a Fair Deal? - WMGI, IOTS, TTPHACCESSWIRE
05:47PM SHAREHOLDER ALERT: WeissLaw LLP Investigates Tetraphase Pharmaceuticals, Inc.PR Newswire
Mar-17-20 02:15PM Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – WLTW, TTPH, ASRT, MEETGlobeNewswire
Mar-16-20 09:10PM TETRAPHASE PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MergerACCESSWIRE
08:10PM Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies - TTPH, CORVACCESSWIRE
Mar-16-20 11:30AM Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger AgreementBusiness Wire
Mar-12-20 11:30AM Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Achievements and Key 2020 MilestonesBusiness Wire
Mar-05-20 05:30PM Tetraphase Pharmaceuticals (TTPH) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks
Jan-23-20 12:24PM The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus TreatmentBenzinga
Jan-22-20 11:45PM Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-MarketBusiness Wire
Dec-03-19 01:40AM Edited Transcript of TTPH earnings conference call or presentation 12-Nov-19 9:30pm GMTThomson Reuters StreetEvents
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with eravacycline through investigating Gram-negative infections treated with eravacycline (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of eravacycline with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; and TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize eravacycline for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)